No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
Abstract The use of proton pump inhibitors (PPIs) has been proposed as a potential risk factor for neurodegenerative diseases, but little is known regarding its role in amyotrophic lateral sclerosis (ALS). We therefore aimed to assess the association of PPI use with the subsequent risk of ALS, and p...
Guardado en:
Autores principales: | Hakan Cetin, Jiangwei Sun, Catarina Almqvist, Berthold Reichardt, Matthias Tomschik, Fritz Zimprich, Fang Fang, Caroline Ingre |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f9bb24ad6dd747789e8a5deeea35072a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Delirium in the geriatric unit: proton-pump inhibitors and other risk factors
por: Otremba I, et al.
Publicado: (2016) -
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
por: Anne T Nies, et al.
Publicado: (2011) -
The proton-pump inhibitor lansoprazole enhances amyloid beta production.
por: Nahuai Badiola, et al.
Publicado: (2013) -
Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
por: Zhang XY, et al.
Publicado: (2021) -
Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy.
por: Hyun-Jung Lee, et al.
Publicado: (2021)